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The androgen receptor undergoes an androgen-spe-
cific NH2- and COOH-terminal interaction between NH2-
terminal motif FXXLF and activation function 2 in the
ligand binding domain. We demonstrated previously
that activation function 2 forms overlapping binding
sites for the androgen receptor FXXLF motif and the
LXXLL motifs of p160 coactivators. Here we investigate
the influence of the NH2- and COOH-terminal interac-
tion on androgen receptor function. Specificity and rel-
ative potency of the motif interactions were evaluated
by ligand dissociation rate and the stability of chimeras
of transcriptional intermediary factor 2 with full-length
and truncated androgen or glucocorticoid receptor. The
results indicate that the androgen receptor activation
function 2 interacts specifically and with greater avidity
with the single FXXLF motif than with the LXXLL motif
region of p160 coactivators, whereas this region of the
glucocorticoid receptor interacts preferentially with
the LXXLL motifs. Expression of the LXXLL motifs as a
fusion protein with the glucocorticoid receptor resulted
in loss of agonist-induced receptor destabilization and
increased half-time of ligand dissociation. The NH2- and
COOH-terminal interaction inhibited binding and acti-
vation by transcriptional intermediary factor 2. We con-
clude that the androgen receptor NH2- and COOH-ter-
minal interaction reduces the dissociation rate of bound
androgen, stabilizes the receptor, and inhibits p160 co-
activator recruitment by activation function 2.
The androgen receptor (AR)1 is a member of the steroid
receptor family of nuclear receptors that act as ligand-depend-
ent transcriptional regulators. The AR shares with other ste-
roid receptors an overall structural arrangement that includes
a COOH-terminal ligand binding domain, central DNA binding
region, and a less well conserved NH2-terminal region (Fig. 1).
Within these domains are two major transactivation regions,
activation function 1 in the NH2-terminal region and activation
function 2 (AF2) in the ligand binding domain. The NH2-ter-
minal activation function 1 region, although not well defined,
requires androgen binding for transcriptional activity and ap-
pears to be critical for AR-mediated gene activation. The AF2
region in the ligand binding domain forms a putative hydro-
phobic binding site for the LXXLL motifs of p160 coactivators
(1–6), as recently revealed in the crystal structure of the AR
ligand binding domain (7, 8). The p160 group of transcriptional
coregulators includes steroid receptor coactivator 1 (SRC1),
transcriptional intermediary factor 2 (TIF2, SRC2), and the
SRC3/TRAM1/AIB1/pCIP/ACTR/RAC3 group of activators (9,
10), which are associated with histone acetyltransferase activ-
ity and can recruit CREB-binding protein, pCAF, and other
coactivators required for chromatin modification (11).
The contribution of the AF2 region to AR-mediated tran-
scriptional activity is unclear. Androgen-dependent transcrip-
tional activity of an AR DNA and ligand binding domain frag-
ment (AR-(507–919)) was only observed in cells that
overexpressed TIF2 or SRC1 (12), which suggests that the AR
AF2 inefficiently recruits p160 coactivators. We also showed
recently that AF2 in the AR ligand binding domain can func-
tion in addition as a binding site for the AR NH2-terminal
region. Mutagenesis studies indicated that the androgen-in-
duced interaction between the AR NH2- and COOH-terminal
(N/C) domains is mediated by two LXXLL-related sequences in
the AR NH2-terminal region (see Fig. 1). These are FQNLF
(FXXLF motif) at residues 23–27 and WHTLF (WXXLF motif)
at residues 433–437 (13). In the presence of androgen, the
FXXLF motif interacts with the AR AF2 in the ligand binding
domain, whereas interaction of the WXXLF motif remains to be
characterized (12, 13). Most importantly, the N/C interaction is
selectively induced by ligands that have AR agonist activity in
vivo, such as the high affinity, biologically active androgens
testosterone and dihydrotestosterone and the lower affinity
anabolic steroids. In striking contrast, the N/C interaction is
not induced by ligands that bind the AR and cause its nuclear
transport but fail to induce AR-mediated gene activation in
vivo (14). The N/C interaction therefore appears to be critical
for AR function in vivo as further evidenced by the association
of the androgen insensitivity syndrome with single amino acid
mutations that disrupt the N/C interaction (12, 15).
In the present study we made use of two strategies to test the
effects of the N/C interaction on AR function. We investigated
to what extent the AR AF2 recruits p160 coactivators in the
presence and absence of the N/C interaction in wild-type and
mutant AR. Second, we took advantage of the observation that
the agonist-induced N/C interaction (16), which was also re-
ported for estrogen receptor  (17) and the progesterone recep-
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tor (18), does not occur in the glucocorticoid receptor (GR) (19).
Chimeras were created in which the three LXXLL motif region
of TIF-2 was fused to the NH2-terminal region of AR and GR.
TIF-2 was shown previously to increase the transcriptional
activity of nuclear receptors through interaction of its LXXLL
motifs with the AF2 region of nuclear receptors (3, 5, 12, 13,
20). The effects of an imposed N/C interaction in the
TIF2(LXXLL)3 glucocorticoid receptor chimeras were deter-
mined by measuring rates of ligand dissociation and protein
degradation. The results indicate that two functional effects of
the N/C interaction are agonist-induced receptor stabilization
and inhibition of p160 coactivator recruitment.
EXPERIMENTAL PROCEDURES
Preparation of AR and GR Expression Vectors—pCMVhARL26A/
F27A (AR-FXXAA) is the full-length AR expression vector with the
coding region for 23FQNLF27 changed to 23FQNAA27. ARL26A/F27A/
L436A/F437A (AR-FXXAA/WXXAA) has in addition 433WHTLF437
changed to 433WHTAA437 as described previously (13). AR-(507–919)
codes for the AR DNA binding domain and ligand binding domain
residues 507–919 (21). AR-E897K, AR-I898T, and AR-V716R have
single amino acid mutations in the AF2 region and were previously
described (12). pCMVhAR-W433A/L436A/F437A (AR-AXXAA) was
constructed by digesting glutathione S-transferase-AR-(334 –566)-
W433A/L436A/F437A with BstEII/KpnI, and the fragment was subcloned
in similarly digested pCMVhAR. AR-(1–503)-L26A/F27A (AR-(1–503)-
FXXAA), AR-(1–503)-W433A/L436A/F437A (AR-(1–503)-AXXAA), and
AR-(1–503)-L26A/F27A/W433A/L436A/F437A (AR-(1–503)-FXXAA/A-
XXAA) were created by digesting AR-FXXAA, AR-AXXAA, and AR-
FXXAA/AXXAA, respectively, with KpnI/BamHI and religating the vect-
ors. pCMVhAR142–337L26A/F27A (AR142–337FXXAA) was created
by double PCR mutagenesis by amplifying AR-FXXAA (13), digesting
with BglII/KpnI, and subcloning into pCMVhAR142–337 digested with
the same enzymes. GALAR-(624–919) and GALGR-(486–777) coding for
fusion proteins of the GAL4 DNA binding domain and the AR and GR
ligand binding domains were previously described (12). The GAL4 DNA
binding domain-progesterone receptor fusion protein GAL-progesterone
receptor 636–933 was prepared by PCR-amplifying the coding region for
residues 636–933 in human progesterone receptor B and subcloning the
fragment into pGAL0 (16).
TIF2(LXXLL)3AR-(172–919) and TIF2(LXXAA)3AR-(172–919) were
constructed by PCR-amplifying the 627–780 amino acid region of
pSG5TIF2 and pSG5TIF2 m123, where the latter has the 3 LXXLL
motifs of TIF2 mutated to LXXAA (3, 20). The fragments were digested
with BglII/AflII and subcloned into pCMVhAR digested with the same
enzymes. This removes the first 171 NH2-terminal amino acid residues
from human AR and places the TIF2 sequences NH2-terminal and
in-frame. TIF2(LXXLL)3AR-(172–780)-AXXAA was constructed by
PCR-amplifying the same 627–780-amino acid region of pSG5TIF2. The
fragment was digested as above and subcloned in AR-AXXAA, which
has the 433WXXLF437 motif mutated to 433AXXAA437. SRC1(LXXLL)3
AR-(172–919) was constructed by PCR-amplifying the 611–780-amino
acid region of SRC1a (22, 23), digesting with BglII/AflII, and subcloning
into pCMVhAR digested with the same enzymes, which removes the
NH2-terminal 171 residues of AR. AIB1(LXXLL)3AR-(172–919) was
constructed by PCR-amplifying the 600–770-amino acid region of AIB1
(24), digesting with BglII/AflII, and subcloning into pCMVhAR digested
with the same enzymes, which removes the first 171 human AR
residues.
TIF2(LXXLL)3GR-(132–777) and TIF2(LXXAA)3GR-(132–777) were
constructed by PCR-amplifying the 627–780 residue region of pSG5T-
IF2 or pSG5TIF2 m123 as above. The fragments were digested with
KpnI/SalI and subcloned into pCMVhGR digested with the same en-
zymes. This removes 131 NH2-terminal amino acid residues of human
GR. TIF2(LXXLL)3GR and TIF2(LXXAA)3GR were constructed by
PCR-amplifying the 2–132-amino acid region of pCMVhGR and sub-
cloning the SalI fragment into TIF2(LXXLL)3GR-(132–777) and
TIF2(LXXAA)3GR-(132–777). This reinserts the NH2-terminal 2–132
residues of GR. The sequence of all PCR-amplified regions was verified
by automated DNA sequencing.
Transcriptional Assays—Cell lines and transfection methods were
selected to optimize transcriptional activity (CV-1 or HeLa cells) or
expression levels (COS cells). Among these different cell lines we did not
observe qualitative differences in response. Monkey kidney CV1 cells
were plated at 4.2  105 cells/6-cm dish in 5% bovine calf serum in
Dulbecco’s modified Eagle’s medium (DMEM) containing 20 mM Hepes,
pH 7.2, penicillin and streptomycin, and 2 mM L-glutamine in a 5% CO2
incubator at 37 °C. The same day 0.1 g/plate of pCMVhAR or
pCMVhGR wild-type or mutant expression vectors and 5 g/plate of
mouse mammary tumor virus luciferase reporter vector were separated
into aliquots for 6 plates/14-ml Falcon tubes and stored at 50 °C
overnight. The next day 0.21 ml of H20/plate and 30 l/plate of freshly
prepared 2 M CaCl2 were added to the DNAs followed by 0.24 ml 2
Hepes-buffered saline/plate (0.28 M NaCl, 1.5 mM Na2HPO4, 0.05 M
Hepes, pH 7.2) while vortexing. After 30 min at room temperature to
allow for calcium phosphate precipitation, the mixture was briefly vor-
texed, and 0.475 ml was added to each plate containing 4 ml of 5%
bovine calf serum in DMEM. The cells were incubated for 4 h, the media
were aspirated, and the cells were incubated for 3 min with 1.5 ml of
15% glycerol in DMEM containing 5% bovine calf serum followed by a
4-ml phosphate-buffered saline wash. Cells were placed in 4 ml of
serum-free, phenol red-free DMEM with and without hormones and
incubated overnight. The following day, serum-free media with and
without hormone were replaced, and the cells were incubated 24 h. The
next day cells were washed with 4 ml of phosphate-buffered saline and
aspirated dry, 0.5 ml of lysis buffer (25 mM Trizma (Tris base) phos-
phate, pH 7.8, 2 mM EDTA, 1% Triton X-100) was added, and 0.1 ml
analyzed for luciferase activity using a Monolight luminometer.
To determine transcriptional activity induced by the GAL4 DNA
binding domain and receptor ligand binding domain fusion proteins,
HeLa cells plated at 3  105 cells/6-cm dish in minimal essential
medium (MEM) containing 10% fetal bovine serum, penicillin and
streptomycin, and 2 mM L-glutamine in a 5% CO2 incubator at 37 °C.
Cells were transfected with 0.25 g each/plate of the GAL4-AR ligand
binding domain, GAL4-GR ligand binding domain, and GAL4-proges-
terone receptor ligand binding domain vectors described above,
pSG5TIF2 and G5E1b-luciferase reporter, which contain 5 tandem
GAL4 binding sites. The day after plating, medium was replaced with
fresh MEM containing 10% fetal bovine serum. DNA was combined
with 0.15 ml of EC buffer/plate (Qiagen) and 4 l of enhancer/plate,
vortexed, and incubated for 5 min at room temperature. Effectene
reagent (Qiagen, 4 l/plate) was added, vortexed for 10 s, and incubated
for 10 min. MEM containing 10% serum was added (1 ml/plate) and
mixed, and 1 ml of the DNA solution was added to each plate. After
incubation overnight at 37 °C, cells were washed with 4 ml of phos-
phate-buffered saline, and 4 ml of serum-free, phenol red-free MEM
with and without hormones was added per plate as indicated. The next
day cells were washed with phosphate-buffered saline and harvested in
0.5 ml of lysis buffer described above and analyzed for luciferase
activity.
Ligand Dissociation Rate Studies—Monkey kidney COS cells were
plated at 0.4  106 cells/well in 6-well plates in 3 ml of 10% bovine calf
serum in DMEM containing 20 mM Hepes, pH 7.2, penicillin and strep-
tomycin, and 2 mM L-glutamine in a 5% CO2 incubator at 37 °C. Cells
were transfected with 2 g/well pCMVhAR or pCMVhGR wild-type or
mutant DNA using 0.95 ml/well of 1.08 TBS (TBS: 0.14 M NaCl, 3 mM
KCl, 1 mM CaCl2, 0.05 mM MgCl2, 0.9 mM NaH2PO4, and 25 mM Tris, pH
7.4) and 0.11 ml/well of 500 mg/ml DEAE-dextran. Media were aspi-
rated, 1 ml of DNA solution was added, and the cells were incubated for
30 min at 37 °C. Media were aspirated, and 3 ml of a chloroquine-
medium solution (1 ml of 5 mg/ml chloroquine/100 ml DMEM contain-
ing 10% bovine calf serum) was added per well. Cells were incubated for
3 h at 37 °C. Media were aspirated, and the cells were incubated for 4
min at room temperature with 1 ml of 15% glycerol in DMEM contain-
ing 10% bovine calf serum. The glycerol medium was aspirated, and the
cells were washed with 3 ml of TBS. Cells were placed with 3 ml of
DMEM containing 10% bovine calf serum at 37 °C. After 48 h, the
medium was aspirated, and 0.6 ml of labeling medium was added
containing 5 nM [3H]R1881 (methyltrienolone, 17-[methyl-3H]R1881,
70–87 Ci/mmol, PerkinElmer Life Sciences) for AR or 8 nM [3H]dexa-
methasone ([1,2,4,6,7-3H]dexamethasone, 84 Ci/mmol, Amersham
Pharmacia Biotech) for GR and incubated for 2 h at 37 °C. Sufficient
wells were labeled to allow multiple time points for specific and non-
specific binding, the latter determined by incubating in the presence of
a 100-fold excess of unlabeled hormone. Dissociation rate studies per-
formed at 35 °C were initiated by adding to the labeling media a
10,000-fold molar excess of unlabeled hormone (0.1 ml/well). Cells were
carefully washed once with 3 ml of phosphate-buffered saline at differ-
ent time intervals and harvested in 0.5 ml of 10 mM Tris, pH 6.8, 2%
SDS and 10% glycerol, and radioactivity was determined by scintilla-
tion counting.
Immunoblots—Relative expression levels and stability of wild-type
and mutant AR and GR were determined by immunoblot analysis. COS
cells were plated in DMEM containing 10% bovine calf serum at 1.6 
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106 cells/10-cm dish and the next day incubated for 3 h at 37 °C with 3
ml/plate containing 10 g of expression vector DNA, 2.85 ml of 1.08
TBS, and 0.33 ml of 5 mg/ml DEAE-dextran solution. The DNA mix was
aspirated, and the cells were treated with 3 ml of chloroquine medium
(see paragraph above) per well. Cells were incubated for 3 h at 37 °C
and then with 3 ml of glycerol media as described above, washed once
with 8 ml of TBS, and incubated in DMEM containing 10% bovine calf
serum at 37 °C. The next day cells were placed in phenol red-free,
serum-free media with or without 0.5 M DHT or 1 M dexamethasone
and incubated for 24 h. Cells were washed in 8 ml of cold phosphate-
buffered saline and harvested in 1 ml of phosphate-buffered saline,
centrifuged, and solubilized in 0.2 ml of 50 mM Tris, pH 7.5, 0.15 M
NaCl, 0.5% Nonidet P-40, 50 mM NaF, 1 mM NaVO3, 1 mM dithiothre-
itol, 1 mM phenylmethylsulfonyl fluoride, and Sigma protease inhibitor
mixture for mammalian cells (P8340). Protein concentrations were de-
termined using the Bio-Rad protein assay with bovine serum albumin
as standard. Extracts were separated on 10% acrylamide gels contain-
ing SDS and analyzed by immunoblot for GR using rabbit polyclonal
anti-human GR antibody (Affinity BioReagents) at 1:2500 dilution. AR
was detected on immunoblots using mouse monoclonal AR antibody
F39.4.1 raised against human AR peptide residues 302–321 (25) (Bio-
genex, San Ramon, CA) and used for immunoblots at 1:10,000 dilution
or rabbit polyclonal antibody C19 raised against human AR peptide
residues 901–919 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and
used at 0.2 g/ml. Secondary antibody goat-anti-mouse IgG or goat
anti-rabbit IgG conjugated to horseradish peroxidase (Amersham Phar-
macia Biotech) were used for detection by enhanced chemiluminescence
(Pierce).
Degradation Rate Studies—Degradation rates of AR and mutants
were determined at 35 °C in the presence of 5 nM DHT by pulse-chase
[35S]methionine labeling in transiently transfected COS cells as previ-
ously described (19). The full-length AR mutants analyzed included
AR-E897K, AR-I898T, and AR-V716R, which are mutations in the AF2
region of the ligand binding domain (12).
RESULTS
Specificity of the NH2-terminal Motif in the N/C Interac-
tion—Mutations in AR NH2-terminal sequences
23FQNLF27
(FXXLF motif) and 433WHTLF437 (WXXLF motif) (Fig. 1) dis-
rupt the N/C interaction, which results in an increase in the
dissociation rate of bound androgen. As previously reported
(13), the dissociation half-time (t1⁄2) of the radiolabeled syn-
thetic androgen [3H]R1881 measured at 35 °C was 158 min for
full-length AR and decreased to 89 min by mutating FXXLF to
FXXAA. Mutation of WXXLF to WXXAA by itself had no effect
on the androgen dissociation rate (13), whereas mutating both
FXXLF and WXXLF to FXXAA and WXXAA decreased the t1⁄2
to 43 min (Fig. 2A and Fig. 3). Mutations in both NH2-terminal
motifs resulted in a ligand dissociation rate equal to that ob-
served for AR-(507–919) (t1⁄2 44 min), a mutant that lacks the
entire NH2-terminal region (Fig. 2B and Fig. 3).
We used the same strategy to test for the relative effective-
ness of LXXLL motifs of TIF2 to interact with AF2 in the AR
ligand binding domain. TIF2-AR chimeras were created in
which AR amino acid residues 1–171 containing the FXXLF
motif were replaced by TIF2 residues 627–780 that include the
3 LXXLL motif region (3). TIF2(LXXLL)3AR had a dissociation
half-time for [3H]R1881 of 97 min (Fig. 2B, TIFLXL3 and Fig.
3), which suggested that the interaction of the 3 TIF2 LXXLL
with the AR ligand binding domain is weaker compared with
that of the single AR FXXLF motif. Specificity of the interac-
tion in TIF2(LXXLL)3AR was assessed in two control experi-
ments. Mutation of the 3 LXXLL motifs in TIF2 to LXXAA (Fig.
2B, TIFLXA3AR and Fig. 3) and of the second N/C AR inter-
action domain WXXLF to AXXAA similarly decreased the dis-
sociation half-time of TIF2(LXXLL)3AR from 97 min to 60
min, which was 15 min longer than the t1⁄2 of 44 min for
AR-(507–919) (Fig. 2B and Fig. 3). The results support a lim-
ited interaction between the three LXXLL motifs of TIF2 and
the AR ligand binding domain compared with that observed
with the single AR NH2-terminal FXXLF sequence.
The relevance of ligand dissociation studies with the
TIF2/AR chimeras was tested further by creating TIF2/GR
chimeras. We chose the GR because we had found previously
that deletion of the GR NH2-terminal region (residues 1–398)
did not change the rapid dissociation rate of [3H]dexametha-
sone (19), supporting the absence of an N/C interaction in GR.
Replacing NH2-terminal GR amino acid residues 1–131 with
the same (LXXLL)3-containing region of TIF2 dramatically
slowed the dissociation half-time of [3H]dexamethasone from
GR from 31 to 168 min (Fig. 2C, TIFLXL3GR and Fig. 3). The
effectiveness of the LXXLL motifs to slow ligand dissociation
from GR in the TIF2-GR chimera contrasted the relative in-
ability of this region to slow the dissociation rate of [3H]R1881
from TIF2(LXXLL)3/AR-(172–919)/AXXAA (t1⁄2 64 min) when
compared with AR-FXXAA/WXXAA (t1⁄2 43 min) and AR-(507–
919) (t1⁄2 44 min). The results suggest a much more effective
interaction of the p160 coactivator LXXLL motifs with the GR
ligand binding domain compared with that with the AR ligand
binding domain. Remarkably, with the NH2-terminal insertion
of the TIF2 LXXLL motif region, the dissociation half-time of
[3H]dexamethasone from GR decreased to the same slow dis-
sociation half-time as observed for [3H]R1881 from AR caused
by the N/C interaction with the naturally occurring FXXLF
motif. When the TIF2 LXXLL motifs were mutated in the
TIF2-GR chimera to TIF2(LXXAA)3GR-(132–777), the ligand
dissociation half-time was indistinguishable from that of wild-
type GR (t1⁄2 28 min, Fig. 2C, TIFLXA3GR and Fig. 3). These
results demonstrate that it was the LXXLL motifs in the TIF2
fragment that simulated an N/C interaction in GR, causing a
dramatic reduction in dissociation half-time of [3H]dexametha-
sone. The same dependence on the LXXLL motifs was obtained
using fusion proteins with the TIF2 (LXXLL)3 region expressed
at the NH2 terminus of full-length GR (Fig. 3).
We compared the relative effects of the (LXXLL)3 region of
TIF2 with those of two other members of the p160 coactivator
family. Replacement of the NH2-terminal 171 amino acid res-
idues of AR with the (LXXLL)3 motif regions of SRC1 or AIB1
indicated that these regions of SRC1 (t1⁄2 58 min) and AIB1 (t1⁄2
51 min) in the chimeras each slowed the ligand dissociation
rate to less of an extent than the same region of TIF2 (t1⁄2 97
min) and considerably less than the reduction induced by AR
FXXLF (t1⁄2 158 min, Fig. 3). Taken together, the data of Figs.
1–3 indicate that none of the LXXLL motifs in the 3 p160
coactivators tested was as effective as the single FXXLF motif
in AR in slowing the dissociation rate of bound androgen. The
results suggest that the AF2 region of AR interacts preferen-
tially with the FXXLF motif. The results raised the question of
whether these LXXLL motifs of the p160 coactivators can com-
pete for the AR interdomain N/C interaction and activate the
AR through the AF2 region of the ligand binding domain. We
tested this in cotransfection assays with increasing amounts of
TIF2 DNA.
Influence of the N/C Interaction on TIF2 Activation of AF2—
The ability of the N/C interaction to influence AR activation by
FIG. 1. Schematic diagram of the human AR with 919 amino
acid residues comprised of the FXXLF motif (23FQNLF27),
WXXLF motif (433WHTLF437), AF1 (residues 142–337), AF2 in the
ligand binding domain, the DNA binding domain (DBD, resi-
dues 559–624), and the ligand binding domain (LBD, residues
676–919).
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the p160 coactivators was assessed by measuring transcrip-
tional activation of AR and AR mutants and, in control exper-
iments, of the TIF2/GR chimeras that mimicked the N/C inter-
action of the AR. In initial studies, we compared the intrinsic AF2
activities of the ligand binding domains of AR, the progesterone
receptor, and GR in GAL4-DNA binding domain fusion proteins
and their relative activation by TIF2 in the absence of the
activation function 1 NH2-terminal region. Intrinsic androgen-
dependent AR AF2 activity was not detected as previously
reported (12), whereas GAL4-ligand binding domain fusion
proteins of progesterone receptor and GR-mediated 6- and 33-
fold induction, respectively, in the presence of hormone (Fig. 4).
TIF2 overexpression resulted in only a 23-fold activation of
GAL-AR ligand binding domain compared with the 197- and
193-fold induction of GAL-progesterone receptor ligand binding
domain and GALGR-ligand binding domain, respectively, in
the presence of hormone (Fig. 4). The results indicate that
compared with the progesterone receptor and GR ligand bind-
ing domain, the AR ligand binding domain has inherently weak
AF2 activity that could be overcome to some extent by TIF2
overexpression.
The high transcriptional activity of the AR NH2-terminal
activation function 1 region (amino acid residues 142–337,
Fig. 1) (26) makes it difficult to measure AF2 activity in the
presence of activation function 1. A deletion mutant
(AR142–337) was therefore used in which the NH2-terminal
transactivation domain residues 142–337 were deleted, but
the N/C interaction remained intact, as indicated by two
hybrid assays (12) and a ligand dissociation rate equivalent
to wild-type AR (19). Increasing the amount of transfected
pSG5TIF2 expression vector DNA from 0.2 to 5 g was rela-
tively ineffective in activating AR142–337, with only a 12-
FIG. 2. Dissociation rate studies of wild-type and mutant AR and GR. Dissociation half-times of bound [3H]R1881 from AR and
[3H]dexamethasone from GR were determined in COS cells transfected as described under “Experimental Procedures.” In A the full-length
pCMVhAR (AR-(1–919) (AR)) and mutants included 23FQNLF27 changed to 23FQNAA27 (FXXAA), and this mutation combined with 433WHTLF437
changed to 433WHTAA437 (FXXAA/WXXAA). In B the AR mutants included AR-(507–919), substitution of the AR NH2-terminal 171-amino acid
residues with TIF2 residues 627–780 containing the 3 LXXLL motif region (TIF2(LXXLL)3AR-(172–919), TIFLXL3AR), and the same vector except
the last two leucines of each LXXLL motif changed to alanine (TIF2(LXXAA)3AR-(172–919), TIFLXA3AR). In C the NH2-terminal 131-amino acid
residues of GR were replaced by TIF2 residues 627–780 containing the 3 LXXLL motif region (TIF2(LXXLL)3GR-(132–777), TIFLXL3GR) and the
same vector except with the last two leucines of each LXXLL motif changed to alanine (TIF2(LXXAA)3GR-(132–777), TIFLXA3GR). Dissociation
half-times are summarized in Fig. 3.
FIG. 3. Schematic diagram of AR
and GR mutants and summary of dis-
sociation half-times. Indicated sche-
matically are mutants described under
“Experimental Procedures” and the disso-
ciation half-times (in min)  S.D.
determined from three independent
experiments at 35 °C. Also indicated are
the DNA binding domain (DBD) and
ligand binding domain (LBD). DEX,
dexamethasone.
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fold activation detected with 5 g TIF2 DNA (Fig. 5A). In
striking contrast, with a construct in which the N/C interac-
tion was weakened by changing the 23FXXLF27 motif to
23FXXAA27 (AR142–337FXXAA, Fig. 5A), TIF2 was about
100 times more effective in increasing AR-mediated transac-
tivation based on the amount of transfected TIF2 DNA. A
similar activation of 12–13-fold was observed using 5 g of
TIF2 with AR142–337 or 0.05 g of TIF2 with AR142–
337FXXAA. However, TIF2 activation of AR142–
337FXXAA was less than that observed when the entire
NH2-terminal region was deleted (Fig. 5A). The weaker acti-
vation by TIF2 of AR142–337FXXAA compared with that
with AR-(507–919) likely resulted from the presence of the
433WHTLF437 sequence in AR142–337FXXAA, as this
WXXLF motif contributes to the N/C interaction (13) and
therefore may partially inhibit TIF2 recruitment by AF2.
We also tested transcriptional coactivation of AF2 using a
TIF2 mutant in which all three LXXLL motifs were changed to
LXXAA. TIF2(LXXAA)3 did not coactivate with AR142–337,
AR142–337FXXAA, or AR-(507–919) above the low intrinsic
levels observed with the mutant AR alone (Fig. 5B). Especially
striking was the decrease in transcriptional activation with
AR142–337FXXAA and AR-(507–919) from 179- and 290-fold
with TIF2 to near background levels with the TIF2(LXXAA)3
mutant. The results of Figs. 5, A and B, suggest that the
androgen-induced AR N/C interaction mediated by the FXXLF
and WXXLF motifs inhibits p160 coactivator interaction with
AF2 in the ligand binding domain. Mutations in the FXXLF
region were required to significantly overcome the androgen-
induced inhibition imposed by the N/C interaction on p160
coactivator recruitment by AF2.
Similar dose-response studies were performed using TIF2-GR
chimeras. Introducing the putative N/C interaction in TIF2-
(LXXLL)3GR-(132–777) resulted in a reduced response to TIF2
activation compared with that observed with the
TIF2(LXXAA)3GR-(132–777) mutant (Fig. 5C). A 10-fold higher
amount of TIF2 was required to activate TIF2(LXXLL)3GR-(132–
777) (0.5 g of TIF2, 160-fold) above background levels compared
with 0.05 g, the lowest level of TIF2 tested with the LXXAA
mutant (142-fold, Fig. 5C). Thus, in agreement with results with
AR, the N/C interaction imposed in GR by insertion of the NH2-
terminal LXXLL motifs attenuated activation of the receptor by
TIF2. It is nevertheless noteworthy that increased TIF2 expres-
sion (5 g of pSG5TIF2 DNA) was effective in overcoming the
inhibition created by the artificially induced N/C interaction
in GR, suggesting that a coregulatory protein with a binding
region of similar or greater affinity for AF2 can compete more
efficiently for the N/C interaction if it is expressed at suffi-
ciently high levels.
Effect of the FXXLF, WXXLF, and LXXLL Motifs on Receptor
Stabilization—An unusual property of the AR is its dramatic
stabilization by agonist binding (27), which previous data sug-
gested is mediated by the N/C interaction (15). In contrast,
most steroid receptors including the estrogen receptor  (28,
29), thyroid hormone receptor (30), GR (31), and progesterone
receptor (32) undergo agonist-induced decreases in receptor
levels. To further investigate the contribution of the N/C inter-
action to androgen-induced AR stabilization, we determined
the effects of mutations in the NH2-terminal FXXLF and
WXXLF interaction motifs on AR levels by immunoblot analy-
sis. The addition of 0.5 M DHT to the growth media resulted in
a dramatic increase in AR protein (Fig. 6A, lanes 2 and 3),
indicating androgen-induced receptor stabilization. In con-
trast, the FXXAA as well as the FXXAA/AXXAA double mutant
AR proteins were detected at similar levels in the absence and
presence of DHT (Fig. 6A, lanes 4–7). We also noted that in the
absence of androgen there was a reproducible increase in the
levels of these AR mutants relative to wild-type AR. The results
support a role of the FXXLF and WXXLF-mediated N/C inter-
action in ligand-induced AR stabilization.
We further investigated the influence of the FXXLF and
WXXLF-mediated N/C interaction on AR stabilization by coex-
pression of the COOH-terminal fragment AR-(507–919) that
contains the DNA and ligand binding domains together with
wild-type AR NH2-terminal fragment AR-(1–503) and AR-(1–
503) fragments containing the FXXAA and AXXAA mutations.
Coexpression of AR-(507–919) with wild-type AR-(1–503) re-
sulted in a modest increase in AR-(507–919) levels assayed in
the presence of 0.5 M DHT (Fig. 6B, lanes 1 and 2). Mutations
in the FXXLF, WXXLF, or both motifs in AR-(1–503), which
decrease the N/C interaction between AR-(1–503) and AR-
(507–919), result in reduced protein levels of AR-(507–919),
although surprisingly, no major changes in protein levels of the
AR-(1–503) fragments were observed (Fig. 6B). The data fur-
ther support an NH2-terminal FXXLF- and WXXLF-motif role
in androgen-induced AR stabilization.
We made use of the TIF2-GR chimeras to substantiate the
role of the N/C interaction in receptor stabilization. Full-length
GR undergoes a striking agonist-induced decrease in receptor
levels with the addition of 1 M dexamethasone (Fig. 6C, lanes
1 and 2). In contrast, the TIF2-GR chimera TIF2(LXXLL)3GR-
(132–777), which was shown above to dramatically slow the
dissociation half-time of bound [3H]dexamethasone (see Fig. 2C
and Fig. 3), exhibited loss of dexamethasone-induced GR de-
stabilization (Fig. 6C, lanes 3 and 4). When the last two leucine
residues in each of the three LXXLL motifs were mutated to
alanine in TIF2(LXXAA)3GR-(132–777), which was shown
above to reverse the ligand dissociation half-time to that of
wild-type GR, degradation of the TIF2-GR chimera was indis-
tinguishable from that of wild-type GR (Fig. 6C, lanes 5 and 6).
Similar results were observed with the TIF2(LXXLL)3GR chi-
meras in which the TIF2 fragment was expressed as a fusion
FIG. 4. Intrinsic AF2 activity of the AR, progesterone receptor,
and GR ligand binding domains. DNA (0.25 g/plate) for the GAL4
DNA binding domain and ligand binding domains for AR (GALAR-
(624–919)), progesterone receptor (GALPR-(636–933)) and GR
(GALGR-(486–777)) were transfected into HeLa cells with or without
0.25 g of pSG5TIF2 (TIF2) and 0.25 g of G5E1b-luciferase reporter
using Effectene as described under “Experimental Procedures.” Cells
were incubated in the absence and presence of 50 nM DHT for AR, 50 nM
R5020 for progesterone receptor, and 50 nM dexamethasone for GR.
Luciferase activity was determined as described under “Experimental
Procedures,” and the fold induction relative to the activity was deter-
mined in the absence of hormone is shown above the bars.
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protein with full-length GR, although the extent of stabiliza-
tion was less pronounced (Fig. 6C, lanes 7–10). Taken together
the results indicate that the agonist-induced N/C interaction
increases the half-time of ligand dissociation and allows for
agonist-induced receptor stabilization and the absence of ago-
nist-induced destabilization that is characteristic of wild-type
AR but not GR.
Degradation rates of AR and several AR mutants were de-
termined using [35S]methionine pulse-chase labeling. As sum-
marized in Table I, mutation of the NH2-terminal FXXLF and
WXXLF motifs resulted in degradation rates intermediate be-
tween those of full-length AR and AR-(507–919), as determined
in COS cells at 35 °C. Increased AR degradation in the pres-
ence of 5 nM DHT compared with that of wild-type AR was also
observed for AR AF2 mutants E897K, I898T, and V716R.
These mutations were shown previously to disrupt the N/C
interaction (12). The results support a critical role for the N/C
interaction in androgen-induced AR stabilization.
DISCUSSION
Several lines of evidence indicate that the agonist-induced N/C
interaction between the LXXLL-like sequences 23FQNLF27 and
433WHTLF437 in the AR NH2-terminal region and the AF2 region
in the AR ligand binding domain is specific for AR and required
for functional activity. The N/C interaction is critical to AR func-
tion, because AF2 mutations that disrupt the N/C interaction
without affecting the equilibrium ligand binding affinity cause
the androgen insensitivity syndrome, whereas mutations that
disrupt p160 coactivator binding without affecting the N/C inter-
action have wild-type activity (12, 15). The N/C interaction slows
ligand dissociation and increases AR stability yet interferes with
p160 coactivator recruitment. Like the LXXLL motifs of p160
coactivators (1, 5), the AR FXXLF motif forms an amphipathic
-helix that interfaces within the hydrophobic groove of AF2.
Results of experiments with chimeric receptors indicate the
AR N/C interaction has greater specificity and potency com-
pared with the interaction of AF2 with the LXXLL motifs of
FIG. 5. Effect of TIF2 expression on AR, GR, and TIF2-receptor chimera-mediated transactivation. CV1 cells were transfected using
calcium phosphate precipitation as described under “Experimental Procedures.” with 5 g of mouse mammary tumor virus luciferase reporter
vector and 100 ng of AR or GR expression vector DNA. Shown are the luciferase light units, determined in the absence and presence of 1 nM DHT
or 10 nM dexamethasone with fold induction indicated above the bars. In each part, the data are representative of at least three
independent experiments. A, cells were transfected in the absence or with increasing amounts of pSG5TIF2 DNA from 0.05 to 5 g together with
AR142–337 that lacks AF-1 residues 142–337, AR142–337FXXAA in which the 23FXXLF27 motif was mutated to FXXAA and activation function
1 deleted, and the DNA binding domain and ligand binding domain fragment AR-(507–919). B, CV1 cells were transfected using 0.1 g of the AR
mutants, 5 g of mouse mammary tumor virus luciferase reporter without or with 5 g of pSG5TIF2 (TIF2) or pSG5TIF2(LXXAA)3 (TIF2-LXXAA).
Cells were incubated in the absence and presence of 1 nM DHT, and luciferase activity and fold induction relative to the activity determined in the
absence of DHT are indicated. C, TIF2(LXXLL)3GR-(132–777) and TIF2(LXXAA)3GR-(132–777) were expressed in CV1 cells in the absence and
presence of increasing amounts of pSG5TIF2 DNA as indicated. Cells were incubated in the absence and presence of 10 nM dexamethasone.
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p160 coactivators. In previous studies, AR/GR chimeras only
slightly increased ligand dissociation half-times (19), suggest-
ing that the FXXLF motif interacts less well with the GR AF2
than this region interacts with the TIF2-derived LXXLL mo-
tifs. In unpublished studies,2 glutathione S-transferase affinity
matrix assays showed that TIF2 LXXLL motif-containing frag-
ments interact with the estrogen receptor  ligand binding
domain, whereas the AR FXXLF fragment does not.
The AR AF2 region only weakly recruits p160 coactivators
compared with the AF2 region of the progesterone or glucocor-
ticoid receptor. This relatively weak interaction is further hin-
dered by the N/C interaction. The hinge region of AR (residues
628–646) was reported to contribute to the low transcriptional
activity of AR AF2 (34). However in our unpublished studies,2
deletion of hinge residues 624–647 only minimally increased
AR AF2 transcriptional activity of a GAL4 fusion protein with
the AR ligand binding domain expressed in HeLa cells and
resulted in a similar increase in the N/C interaction. The lower
transcriptional activity of the AR AF2 region relative to other
nuclear receptors more likely results from sequence diver-
gence-induced structural differences and by the N/C
interaction.
One functional consequence of the agonist-induced AR N/C
interaction may be to present a novel surface to attract AR-
specific coactivators. A LIM domain, heart-specific protein
FHL2 (35) is a reported AR coactivator that interacts with
full-length AR but not with the NH2- or COOH-terminal region
(36), suggesting it recognizes an N/C interaction-induced con-
formation. The AR N/C interaction may contribute to the rec-
ognition of weaker androgen response elements whose regula-
tion is androgen-specific (37).
Most steroid receptors undergo ligand-induced down-regula-
tion resulting from ubiquitin-mediated proteolysis by the pro-
teosome. Rates of receptor degradation have been correlated
with activation potency (38), and activation domains and deg-
radation signals can overlap (39). Proteosome-mediated degra-
dation of estrogen receptor  (29, 40) was linked with coacti-
vator recruitment and transcriptional potency. Mutations in
the estrogen receptor  AF2 region at residues critical for
coactivator recruitment stabilized the receptor (41), raising the
possibility that p160 coactivator interaction with ligand-bound
receptors is required for receptor degradation. The thyroid
hormone receptor is also rapidly degraded by the proteosome
(30), but ligand-dependent degradation of retinoid X receptor
did not require transcriptional activity or interaction with p160
coactivators (42).
In our unpublished studies2 AR degradation is mediated by
the proteosome; however, in contrast to most nuclear receptors,
AR and the vitamin D receptors (43) undergo agonist-induced
stabilization. For the vitamin D receptor, inhibition of ubiq-
uitin-proteosome-mediated degradation amplified the tran-
scriptional response (43–45). For AR, it remains to be estab-
lished whether in vivo transcriptional activity at certain
androgen response elements requires the N/C interaction or
the resulting agonist-induced increase in AR stability. The
5-fold reduced dissociation half-time of bound dexamethasone
and reversal of the dexamethasone-induced decrease in GR
levels in the TIF2-GR chimeras dramatically demonstrated the
influence of the N/C interaction on receptor stabilization. This
artificial N/C interaction in GR resulted in ligand dissociation
and stability properties similar to those of wild-type AR.2 B. He and E. M. Wilson, unpublished material.
FIG. 6. Immunoblot analysis of AR, GR, and mutants in the
presence and absence of hormone. Plasmids were expressed in COS
cells in the presence and absence of hormone as indicated. Cell extracts
(20 g of protein) were analyzed on 10% acrylamide gels by immunoblot
as described under “Experimental Procedures.” A, full-length wild-type
(WT) and mutant AR expression vectors included pCMV5 parent vector
lacking AR sequence (p5, lane 1), wild-type pCMVhAR (WT, lanes 2 and
3), AR-FXXAA (lanes 4 and 5), and AR- FXXAA/AXXAA (lanes 6 and 7).
Cells were incubated 24 h before harvest with or without 0.5 M DHT as
indicated. Immunoblots were developed using the C19 AR COOH-ter-
minal antibody (Santa Cruz). B, AR-(507–919) (5 g, AR DNA and
ligand binding domain) was expressed in the presence of an equivalent
molar amount of pCMV5 empty vector DNA (3 g, lane 1) or 5 g of
AR-(1–503) coding for the AR NH2-terminal region (lane 2), AR-(1–503)-
FXXAA (lane 3), AR-(1–503)-AXXAA (lane 4), or AR-(1–503)-FXXAA/
AXXAA (lane 5). Twenty-four h after transfection, cells were incubated
with 0.5 M DHT for another 24 h. The blot was probed with COOH-
terminal AR rabbit polyclonal antibody C19 (Santa Cruz) at 0.2 g/ml
to detect AR-(507–919) and with mouse monoclonal antibody F39.4
(Biogenex) at 1:10,000 dilution to detect AR-(1–503). C, the effect of
dexamethasone on GR and TIF2-GR chimera expression levels for full-
length wild-type pCMVhGR (GR, lanes 1–2), TIF2627–780(LXXLL)3GR-
(132–777) (LXXLL-GR-(132–777), lanes 3–4), TIF2627–780(LXXAA)3GR-
(132–777) (LXXAA-GR-(132–777), lanes 5–6), TIF2627–780(LXXLL)3GR
(LXXLL-GR, lanes 7–8), TIF2627–780(LXXAA)3GR (LXXAA-GR, lanes
9–10). Cells were incubated for 24 h before harvest in the absence
(odd-numbered lanes) and presence (even-numbered lanes) of 1 M
dexamethasone (DEX). GR and the TIF2-GR chimeras were detected
using rabbit polyclonal anti-human GR antibody (Affinity
BioReagents).
TABLE I
Degradation half-times determined in the presence of 5 nM DHT
Degradation half-times (in h) were determined in COS cells tran-
siently transfected with the AR or the indicated AR mutants and
analyzed at 35 °C in the presence of 5 nM DHT. Expressed AR was
labeled with [35S]methionine, and pulse-chase analysis was performed
as described under “Experimental Procedures.” Mutations are further
defined under “Experimental Procedures.” Shown are the means and
error of at least three independent experiments.
h
AR 12.0  3.0
AR-(507–919) 2.4  0.2
NH2-terminal mutations
FXXAA 5.6  0.6
FXXAA/WXXAA 7.4  0.8
AF2 mutations
E897K 4.5  1.8
I898T 6.2  0.4
V716R 5.8  0.2
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Dose-response transcription assays where TIF2 is tran-
siently overexpressed as shown here indicate that the AR N/C
interaction blocks AF2 recruitment of p160 coactivators. Tran-
scriptional inhibition is predicted for other p160 coactivators
such as SRC1 that interact with AF2 through LXXLL motifs. It
is not known, however, to what extent inhibition of p160 coac-
tivator recruitment by the N/C interaction limits the activity of
these coactivators in vivo. Neither is it known how the inter-
action of other coactivators such as p300/CREB-binding protein
or ARA70 with the AR is affected by the N/C interaction.
Previous studies indicated that mutation of lysine 720 reduced
the interaction of p160 coactivators with AF2, but this mutant
AR retained full transcriptional activity (12). The correspond-
ing lysine in mouse estrogen receptor  (lysine 366) was re-
quired for p160 coactivator recruitment and estrogen receptor
 transcriptional activity (46).
p160 coactivator overexpression in transient transfection ex-
periments (12) and possibly in vivo in some disease states (47)
may increase steroid receptor transcriptional activity. This was
shown for AR where coactivation by TIF2 was mediated by the
AR NH2-terminal and COOH-terminal regions (12, 48). How-
ever these types of studies do not address whether p160 coac-
tivators increase AR activation when coactivators are present
at normal physiological levels. We showed recently that TIF2
and SRC1 are almost undetectable in human benign hyperplas-
tic prostatic tissue compared with greatly increased levels in
recurrent prostate cancer (47). In recurrent prostate cancer,
overexpression of p160 coactivators may effectively compete for
the N/C interaction through their interaction with the NH2-
and COOH-terminal domains.
N/C interdomain interactions have been reported for other
steroid and nuclear receptors; however, the potency and func-
tional consequences differ. Intracellular phosphorylation of the
A/B NH2-terminal domain of PPAR- reduced ligand binding
affinity (49). Interactions between the hinge-amino-terminal
regions of the progesterone receptor contributed to dimeriza-
tion and increased activation (50), whereas GR seems to lack
an N/C interaction based on ligand dissociation (19) and direct
interaction assays (51). Functional synergism between the
NH2- and COOH-terminal domains was also reported (52, 53).
For estrogen receptor  and , agonist-induced synergism was
mediated by p300/CREB-binding protein and TIF2 binding to
the NH2-terminal region (54, 55). Similarly, in unpublished
studies2 we could not demonstrate direct NH2- and COOH-
terminal domain interactions for estrogen receptor  in gluta-
thione S-transferase affinity matrix studies. CREB-binding
protein and SRC1a were reported to enhance the AR N/C
interaction through an indirect mechanism where coactivators
act as adapters between activation function 1 and AF2 (56).
The glutamine-rich region of SRC1e at residues 1053–1123
interacted with AR NH2-terminal residues 360–494, suggest-
ing SRC1 acts as a bridging molecule to mediate the N/C
interaction (33). p160 coactivators also reportedly increased
the AR N/C interaction, suggesting the N/C interaction is in-
direct. However, the identification of FXXLF and WXXLF mo-
tifs in the AR NH2-terminal region (13) that bind the AF2
region of the ligand binding domain (12) provides strong evi-
dence that the AR N/C interaction is direct. Moreover, tran-
scriptional assays indicate that the agonist-induced N/C inter-
action interferes with the recruitment of p160 coactivators.
The AR FXXLF-AF2 N/C interaction is specific for the bio-
logically active androgens testosterone and DHT and for ana-
bolic steroids. However, the identification of the androgen-
induced FXXLF-AF2 N/C interaction suggests that AR
antagonists can be identified that inhibit or agonists that pro-
mote interactions with other FXXLF or LXXLL motif-contain-
ing proteins. Pharmaceutical ligands that bind AR with mod-
erate or high affinity may promote interactions with related
peptide sequences present in coregulatory proteins. Whether
the FXXLF motif or related sequences occur in AR-specific
coactivators that have sufficient affinity to compete for the
agonist-induced N/C interaction or are induced to interact by
other ligands remains to be established. In the presence of such
ligands, coregulatory proteins might inhibit or compete for the
androgen-induced N/C interaction to regulate tissue-selective
AR-mediated gene activation.
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